HIDDEN2 V1.0
Research type
Research Study
Full title
Hospital Deep Vein Thrombosis Detection Study in Cancer Patients Receiving Palliative Care
IRAS ID
306532
Contact name
Simon Noble
Contact email
Sponsor organisation
Aneurin Bevan University Health Board
Clinicaltrials.gov Identifier
1178, CTR Portfolio Number
Duration of Study in the UK
1 years, 7 months, 31 days
Research summary
The HIDDEN trial aimed to investigate the prevalence of deep venous thrombosis in patients with advanced cancer, aiming to determine prevalence and predictors of femoral deep vein thrombosis in patients admitted to specialist palliative care units (SPCUs). The trial challenged, and changed, existing international thromboprophylaxis guidance in this population. Results were published in The Lancet.
HIDDEN2 seeks to extend the investigation in the same group of patients, admitted in the hospital setting. It is suspected that patients in this group will receive thromboprophylaxis, where evidence for the efficacy or need of this treatment is not robust. Potential issues with both under-treatment (if thromboprophylaxis is not followed) may be less impactful than over-treatment where a small sub-group may experience acute bleeding episodes. The HIDDEN2 trial will seek to identify whether current guidelines are supported by findings of this observational study.
REC name
Wales REC 4
REC reference
22/WA/0037
Date of REC Opinion
16 Mar 2022
REC opinion
Further Information Favourable Opinion